Detalles de la búsqueda
1.
Enhancing global access to cancer medicines.
CA Cancer J Clin
; 70(2): 105-124, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32068901
2.
Allocation of authorship and patient enrollment among global clinical trials in oncology.
Cancer
; 129(18): 2856-2863, 2023 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37382190
3.
Changing the landscape of European School of Oncology-European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemic.
Future Oncol
; 18(25): 2857-2864, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35722882
4.
Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
Breast Cancer Res Treat
; 188(3): 631-640, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34148205
5.
ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test.
J Cancer Educ
; 36(3): 556-560, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31845109
6.
The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resource-Stratified Phased Implementation: Methods and overview.
Cancer
; 126 Suppl 10: 2339-2352, 2020 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32348573
7.
Breast cancer treatment: A phased approach to implementation.
Cancer
; 126 Suppl 10: 2365-2378, 2020 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32348571
8.
Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe.
Oncologist
; 24(1): e30-e37, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30181313
9.
Changing global policy to deliver safe, equitable, and affordable care for women's cancers.
Lancet
; 389(10071): 871-880, 2017 02 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-27814964
10.
The global burden of women's cancers: a grand challenge in global health.
Lancet
; 389(10071): 847-860, 2017 02 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-27814965
11.
CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Lancet Oncol
; 18(7): 917-928, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28592386
12.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Lancet Oncol
; 17(9): 1230-9, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27501767
13.
Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.
Oncologist
; 21(10): 1183-1190, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27401890
14.
PDGF beta targeting in cervical cancer cells suggest a fine-tuning of compensatory signalling pathways to sustain tumourigenic stimulation.
J Cell Mol Med
; 19(2): 371-82, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25311137
15.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
Lancet Oncol
; 15(10): 1137-46, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25130998
16.
Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes.
JMIR Cancer
; 10: e54178, 2024 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38573759
17.
Envisioning Academic Global Oncologists: Proposed Competencies for Global Oncology Training From ASCO.
JCO Glob Oncol
; 10: e2300157, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38603655
18.
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.
J Cardiovasc Pharmacol
; 61(6): 495-504, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23429593
19.
The educational contribution of the college of the European school of oncology (ESCO): A survey analysis of the first three years.
Crit Rev Oncol Hematol
; 192: 104145, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37783317
20.
European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care.
Eur J Cancer
; 187: 105-113, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37146504